Treatment of Pulmonary Mycobacterium kansasii Infection in Rifampicin-Susceptible Disease

Clinical scenario

This protocol addresses pulmonary Mycobacterium kansasii disease in patients where rifampicin susceptibility has been confirmed — that is, rifampicin resistance is absent on susceptibility testing.

Treatment approach

Management centres on a rifampicin-containing combination regimen. The full protocol details which companion agents are used, the permissible frequency options based on disease pattern, and the minimum required duration of therapy.

Complete regimen, frequency guidance, and duration are specified in the structured protocol — not shown here in full.

Clinical target

The primary goal is sputum culture conversion to negative on a rifampicin-based regimen. Expert consultation is recommended if cultures do not convert as expected.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciaa1062

In patients with rifampicin-susceptible M. kansasii pulmonary disease, we suggest a regimen of rifampicin, ethambutol, and either isoniazid or macrolide (conditional recommendation, very low certainty in estimates of effect).
Because sputum conversion at 4 months of rifampicin-based regimens is usually observed, expert consultation should be obtained if cultures fail to convert to negative by that time.

View source ↗